Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

893

Figures (1-5)

161

Tables (1-3)

158

Sum=1250

Publishing Process of This Article

Item

Count

Browse

Download

137

Sum=174

Jan 14, 2025 (publication date) through Apr 9, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Jan 14, 2025; 31(2): 101292
Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.101292

Full Size Figure Download Figure

Figure 5 Remission rates expressed per quartile. A: At week 0; B: At week 48.

Citation: Chaemsupaphan T, Pudipeddi A, Lin HY, Paramsothy S, Kariyawasam VC, Kermeen M, Leong RW. Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study. World J Gastroenterol 2025; 31(2): 101292
URL: https://www.wjgnet.com/1007-9327/full/v31/i2/101292.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i2.101292